Axsome Therapeutics Price Target Cut to $239.00/Share From $256.00 by UBS

What happened

UBS lowered its price target for Axsome Therapeutics to $239.00 per share from $256.00 while keeping a Buy rating on the stock, according to the supplied report.

Confirmed

Global impact / market context

A lower price target means UBS expects less upside than before, though the Buy rating signals it still sees the stock as attractive. This may shape how investors weigh Axsome's current price against the broker's revised view.

Analyst inference

Axsome Therapeutics is a drugmaker covered by UBS analysts who publish ratings and price targets. Such revisions are routine broker updates, and a still-positive rating alongside a cut suggests a more cautious but not negative outlook.

Analyst inference

What to watch

1. UBS maintained its Buy rating on Axsome Therapeutics while reducing the price target to $239.00 from $256.00 per share. Confirmed
2. Watch whether other analysts following Axsome Therapeutics adjust their own price targets after UBS's revision, which could signal broader changes in expectations. Analyst inference
3. Investors should compare UBS's new $239.00 target with the stock's current price to judge whether the implied gain still justifies holding shares. Proposed

Evidence

• Original source link unavailable